Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial

Study limitation reported by the research below: “Open-label design is a key risk of bias; the paper acknowledges this implicitly in its design description.”